
NeuraLight is a software platform that extracts oculometric markers from facial video for pharmaceutical companies measuring disease progression.
neuralight.aiCrawled Nov 4, 2026
Eddy has over 20 years of experience designing AI algorithms and leading teams in signal processing, computer vision, and AI.
Precision biomarkers that quantify functional brain change. Supporting drug development and brain health programs.
NeuraLight introduces an eye-tracking technology that may challenge the **MDS-UPDRS**—the long-standing gold standard for assessing Parkinson’s disease symptoms. The innovation leverages eye-movement data to potentially refine diagnostic accuracy and patient monitoring. Researchers and clinicians evaluate whether this approach could replace or complement traditional motor and non-motor evaluations in clinical practice.
NeuraLight’s biomarkers identify Parkinson’s disease progression markers that the MDS-UPDRS scale—developed by the study’s own researchers—fails to detect. A peer-reviewed multicenter trial involving 280 patients across five countries shows NeuraLight’s superior accuracy in tracking disease progression. The findings highlight gaps in the current gold-standard diagnostic tool.
NeuraLight provides Teitur Trophics with its precision biomarker platform for the **TT-P34 Parkinson’s disease clinical trial**. The partnership aims to enhance patient stratification and therapeutic monitoring by leveraging advanced biomarkers. Teitur Trophics develops neuroprotective treatments, while NeuraLight specializes in precision diagnostics for neurodegenerative diseases.
A healthcare startup secures **$25 million** in funding to develop **AI-driven digital biomarkers** for diagnosing neurological diseases. The technology aims to improve early detection and accuracy beyond traditional human capabilities. The company focuses on leveraging artificial intelligence to address unmet needs in neurological health diagnostics.
NeuraLight raises **$25 million in Series A funding** to advance precision medicine for neurological diseases. The company uses **oculometric data** and **computer vision**—analyzed via smartphones—to track progression in disorders like Alzheimer’s, Parkinson’s, multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS). Its technology aims to enable earlier, more accurate diagnoses through non-invasive eye movement monitoring.